Mal\u00e1rie, nemoc p\u0159en\u00e1\u0161en\u00e1 kom\u00e1ry, z\u016fst\u00e1v\u00e1 v\u00fdznamnou hrozbou, p\u0159edev\u0161\u00edm v Africe, kde ka\u017ed\u00fdm okam\u017eikem usmrt\u00ed jedno d\u00edt\u011b. V\u011bdci a pracovn\u00edci ve ve\u0159ejn\u00e9m zdravotnictv\u00ed dos\u00e1hli pokroku v boji proti mal\u00e1rii, av\u0161ak hled\u00e1n\u00ed \u00fa\u010dinn\u00e9 vakc\u00edny st\u00e1le prob\u00edh\u00e1.<\/p>\n\n
Farmaceutick\u00e1 spole\u010dnost GlaxoSmithKline vyvinula s financov\u00e1n\u00edm od nadace Billa a Melindy Gatesov\u00fdch vakc\u00ednu nazvanou Mosquirix (RTS,S), kter\u00e1 ned\u00e1vno p\u0159ekonala v\u00fdznamnou regula\u010dn\u00ed p\u0159ek\u00e1\u017eku. Evropsk\u00e1 agentura pro l\u00e9\u010div\u00e9 p\u0159\u00edpravky (EMA) doporu\u010dila vakc\u00ednu jako bezpe\u010dnou a \u00fa\u010dinnou pro pou\u017eit\u00ed u ohro\u017een\u00fdch d\u011bt\u00ed v Africe.<\/p>\n\n
A\u010dkoli je schv\u00e1len\u00ed vakc\u00edny Mosquirix v\u00fdznamn\u00fdm krokem vp\u0159ed, je d\u016fle\u017eit\u00e9 poznamenat, \u017ee vakc\u00edna nen\u00ed tak \u00fa\u010dinn\u00e1, jak se p\u016fvodn\u011b doufalo. Ve velk\u00e9 klinick\u00e9 studii sn\u00ed\u017eila v\u00fdskyt mal\u00e1rie p\u0159ibli\u017en\u011b o t\u0159etinu u mal\u00fdch d\u011bt\u00ed v subsaharsk\u00e9 Africe, nedos\u00e1hla v\u0161ak 50% c\u00edle \u00fa\u010dinnosti a je daleko od 95% \u00fa\u010dinnosti, kter\u00e1 se u vakc\u00edn obvykle po\u017eaduje.<\/p>\n\n
Vakc\u00edna Mosquirix nav\u00edc vy\u017eaduje pod\u00e1n\u00ed t\u0159\u00ed d\u00e1vek d\u011btem. V pr\u016fb\u011bhu \u010dasu jej\u00ed \u00fa\u010dinnost sl\u00e1bne, co\u017e vy\u017eaduje posilovac\u00ed d\u00e1vku. Tyto faktory vzbuzuj\u00ed obavy ohledn\u011b anal\u00fdzy n\u00e1klad\u016f a p\u0159\u00ednos\u016f vakc\u00edny, zejm\u00e9na v prost\u0159ed\u00edch s omezen\u00fdmi zdroji.<\/p>\n\n
P\u0159es tato omezen\u00ed EMA rozhodla, \u017ee p\u0159\u00ednosy vakc\u00edny Mosquirix p\u0159evy\u0161uj\u00ed jej\u00ed rizika. Vakc\u00edna je nejpokro\u010dilej\u0161\u00ed ve v\u00fdvoji a spole\u010dnost GlaxoSmithKline ji\u017e pracuje na jej\u00ed druh\u00e9 generaci.<\/p>\n\n
Odborn\u00edci uzn\u00e1vaj\u00ed, \u017ee i \u010d\u00e1ste\u010dn\u011b \u00fa\u010dinn\u00e1 vakc\u00edna by mohla m\u00edt v\u00fdznamn\u00fd dopad na sn\u00ed\u017een\u00ed z\u00e1t\u011b\u017ee mal\u00e1rie. Pro d\u011bti, kter\u00e9 ka\u017edoro\u010dn\u011b prod\u011blaj\u00ed n\u011bkolik z\u00e1va\u017en\u00fdch malarick\u00fdch epizod, by vakc\u00edna mohla potenci\u00e1ln\u011b zm\u011bnit \u017eivot.<\/p>\n\n
Sv\u011btov\u00e1 zdravotnick\u00e1 organizace (WHO) nyn\u00ed rozhodne, zda doporu\u010d\u00ed pou\u017eit\u00ed vakc\u00edny Mosquirix, a poskytne pokyny k jej\u00ed implementaci. Jednotliv\u00e9 zem\u011b se pot\u00e9 budou samostatn\u011b rozhodovat, zda vakc\u00ednu zavedou.<\/p>\n\n
A\u010dkoli vakc\u00edna Mosquirix nen\u00ed dokonal\u00e1, p\u0159edstavuje v\u00fdznamn\u00fd miln\u00edk v boji proti mal\u00e1rii. Neust\u00e1l\u00e9 v\u00fdzkumn\u00e9 a v\u00fdvojov\u00e9 \u00fasil\u00ed spole\u010dnosti GlaxoSmithKline slibuj\u00ed budouc\u00ed v\u00fdvoj \u00fa\u010dinn\u011bj\u0161\u00edch a prakti\u010dt\u011bj\u0161\u00edch vakc\u00edn proti mal\u00e1rii.<\/p>\n\n
Pokud proces schvalov\u00e1n\u00ed prob\u011bhne hladce, prvn\u00ed d\u00e1vky vakc\u00edny Mosquirix by mohly b\u00fdt k dispozici pro d\u011bti v roce 2017, co\u017e p\u0159inese novou nad\u011bji v boji proti t\u00e9to ni\u010div\u00e9 nemoci.<\/p>","protected":false},"excerpt":{"rendered":"
Malarick\u00e1 vakc\u00edna: D\u016fle\u017eit\u00fd miln\u00edk s jist\u00fdmi v\u00fdhradami Pozad\u00ed Mal\u00e1rie, nemoc p\u0159en\u00e1\u0161en\u00e1 kom\u00e1ry, z\u016fst\u00e1v\u00e1 v\u00fdznamnou hrozbou, p\u0159edev\u0161\u00edm v Africe, kde ka\u017ed\u00fdm okam\u017eikem usmrt\u00ed jedno d\u00edt\u011b. V\u011bdci a pracovn\u00edci ve ve\u0159ejn\u00e9m zdravotnictv\u00ed…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[359],"tags":[2133,3706,6750,2862,178],"class_list":["post-3562","post","type-post","status-publish","format-standard","hentry","category-medicine","tag-global-health","tag-malaria","tag-mosquirix","tag-vaccine","tag-public-health"],"_links":{"self":[{"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/posts\/3562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/comments?post=3562"}],"version-history":[{"count":1,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/posts\/3562\/revisions"}],"predecessor-version":[{"id":3563,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/posts\/3562\/revisions\/3563"}],"wp:attachment":[{"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/media?parent=3562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/categories?post=3562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/tags?post=3562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}